STIM Quote, Financials, Valuation and Earnings

Electromed has a net margin of -39.64% compared to Neuronetics's net margin of 12.06%. Neuronetics's return on equity of -189.86% beat Electromed's return on equity of 16.57%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 72.81%. Given that Neuronetics has higher upside potential than Electromed, analysts believe Neuronetics is more attractive than Electromed.

Neuronetics has a beta of 1.922, which suggesting that the stock is 92.179% more volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are larger than Electromed quarterly revenues of $15.7M. Neuronetics's net income of -$12.7M is lower than Electromed's net income of $1.9M. Notably, Neuronetics's price-to-earnings ratio is -- while Electromed's PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.57x versus 3.21x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -39.64% compared to Neuronetics's net margin of 12.62%. Neuronetics's return on equity of -189.86% beat Globus Medical's return on equity of 4.59%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand Globus Medical has an analysts' consensus of $85.17 which suggests that it could grow by 45.34%. Given that Neuronetics has higher upside potential than Globus Medical, analysts believe Neuronetics is more attractive than Globus Medical.

Neuronetics has a beta of 1.922, which suggesting that the stock is 92.179% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.202, suggesting its more volatile than the S&P 500 by 20.197%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are smaller than Globus Medical quarterly revenues of $598.1M. Neuronetics's net income of -$12.7M is lower than Globus Medical's net income of $75.5M. Notably, Neuronetics's price-to-earnings ratio is -- while Globus Medical's PE ratio is 43.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.57x versus 3.24x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -39.64% compared to Neuronetics's net margin of -2201.34%. Neuronetics's return on equity of -189.86% beat VolitionRX's return on equity of --.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 250.96%. Given that VolitionRX has higher upside potential than Neuronetics, analysts believe VolitionRX is more attractive than Neuronetics.

Neuronetics has a beta of 1.922, which suggesting that the stock is 92.179% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are larger than VolitionRX quarterly revenues of $246.4K. Neuronetics's net income of -$12.7M is lower than VolitionRX's net income of -$5.4M. Notably, Neuronetics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.57x versus 57.74x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -39.64% compared to Neuronetics's net margin of 0.18%. Neuronetics's return on equity of -189.86% beat Xtant Medical Holdings's return on equity of -26.62%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 178.22%. Given that Xtant Medical Holdings has higher upside potential than Neuronetics, analysts believe Xtant Medical Holdings is more attractive than Neuronetics.

Neuronetics has a beta of 1.922, which suggesting that the stock is 92.179% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Neuronetics's net income of -$12.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, Neuronetics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.57x versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.